Patent classifications
C12N2501/2304
FACTOR RICH PRODUCTS FROM UMBILICAL CORD MESENCHYMAL STEM CELLS
Factor rich compositions produced from umbilical cord (UC) mesenchymal stem cells (MSCs) are described. Secretory UC MSCs in serum free culture conditions produce a factor rich conditioned medium which may be concentrated and filtered to obtain clinical grade products.
CHIMERIC CELLS COMPRISING DENDRITIC CELLS AND ENDOTHELIAL CELLS RESEMBLING TUMOR ENDOTHELIUM
Disclosed are means, methods and compositions of matter useful for induction of immunological responses towards tumor endothelial cells. In one embodiment the invention teaches fusion of dendritic cells and cells resembling tumor endothelial cells and administration of such chimeric cells as an immunotherapy for stimulation of tumor endothelial cell destruction. In other embodiments pluripotent stem cells are utilized to generate dendritic cells, wherein said dendritic cells are fused with pluripotent stem cell derived endothelial cells created in a manner to resemble tumor endothelial cells.
HYPOXIA-RESPONSIVE CHIMERIC ANTIGEN RECEPTORS
The present invention relates to therapeutic agents, particularly to therapeutic polypeptides and nucleic acids having the capacity for selective expression under conditions of hypoxia, cells incorporating the nucleic acids and their use in therapy, in particular in methods requiring selective expression under conditions of hypoxia, such as typically found in solid cancers. The nucleic acids encode novel hypoxia-responsive chimeric antigen receptors (CARs). The invention also relates to hypoxia-responsive regulatory nucleic acids.
Method For Identifying Epitope On Protein
In one aspect, the present invention provides, for example, an improved method for identifying an epitope on a protein, comprising the following steps: (A) contacting a major histocompatibility complex (MHC molecule)-expressing cell differentiated from a stem cell or a progenitor cell derived therefrom with a target protein; (B) isolating a complex of a peptide contained in the target protein and the MHC molecule from the MHC molecule-expressing cell; and (C) eluting the peptide from the complex and identifying the peptide.
EX VIVO DEVELOPMENT, EXPANSION AND IN VIVO ANALYSIS OF A NOVEL LINEAGE OF DENDRITIC CELLS
Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types that may be used as cancer immunotherapy.
Multiple antigen specific cell therapy methods
The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.
MULTIPLE ANTIGEN SPECIFIC CELL THERAPY METHODS
The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.
PANCREATIC DIFFERENTIATION
In some aspects, disclosed herein are methods and compositions for generating enterochromaffin cells. In some aspects, the methods and compositions disclosed herein relate to use of an inhibitor of IL-4/JAK3 signaling pathway. In other aspects, disclosed herein are cell compositions, pharmaceutical compositions, and medical devices that relate to pancreatic cells that are generated according to the methods disclosed herein.
STIMULATION OF DENDRITIC CELL ACTIVITY BY HOMOTAURINE AND ANALOGUES THEREOF
Disclosed are means, methods, and compositions of matter useful for enhancement of dendritic cell activity. In one embodiment the invention provides the use of GABA agonists such as homotaurine for stimulation of dendritic cell activity. In one embodiment said dendritic cell activity is enhancement of natural killer cell activity and/or of T cell activity. In one embodiment NK cell activity is ability to induce cytotoxicity in neoplastically transformed cells, whereas T cell activity is either cytokine production for CD4 cells or cytotoxicity for CD8 cells.
ENGINEERED ANTIGEN PRESENTING CELLS
Provided herein are various engineered antigen presenting cells, methods of making them and methods of using them.